Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.

Clin TrialsJun 2, 2026 (epub)
Clinical ResearchEndocrinologyCardiology

Kathrine Kold Sørensen, Johan Sebastian Ohlendorff, Anders Munch et al.

✦ AI-curated · Sources linked

In 30 seconds

This re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial, a randomized controlled trial, evaluated the sustained effects of liraglutide on cardiovascular outcomes in patients with diabetes. The sustained treatment analysis showed a 3.5-year risk of the primary composite outcome of 11.4% for liraglutide versus 12.6% for placebo, with a risk difference of 1.1%.

Key findings

  • Intention-to-treat analysis showed 3.5-year risks of 11.8% for liraglutide and 13.3% for placebo.
  • Sustained treatment analysis indicated a risk difference of 1.1% between liraglutide and placebo.
  • No statistically significant differences were found for secondary outcomes at 3.5 years.

Why it matters

Understanding the sustained effects of liraglutide on cardiovascular outcomes is crucial for clinicians managing diabetes patients, as it informs treatment decisions and patient counseling regarding cardiovascular risks.

Source

PubMed · PMID 42227113

Published in Clin Trials. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.